Novartis to Complete Spinoff of Generic Drug Division

Swiss pharmaceutical maker Novartis plans to spin off its Sandoz generic drugs division starting Wednesday, to focus on its core drug R&D business.

Related Keywords

United States ,Switzerland ,American ,Swiss ,Novartis Adrs ,Janeth Cho , ,Novartis ,Sandoz Group ,Swiss Exchange ,Switzerland Based Novartis ,Swiss Performance Index ,Swiss Leader Index ,Eli Lilly ,Article Normal ,Biotechnology Services ,Pharmaceuticals ,Healthcare Life Sciences ,Biopharmaceuticals ,Generic Biosimilar Drugs ,Corporate Changes ,Corporate Strategy Planning ,Ownership Changes ,Corporate Actions ,Corporate Industrial News ,Divestments ,New Companies Creation ,Demergers ,Content Types ,Factiva Filters ,C Amp Ampe Industry News Filter ,Synd ,Biotech And Pharma ,Companies ,Novn Eb ,Ch Novn ,Falcon ,Talc ,Gsk ,Gsk Ln ,Uk Gsk ,Johnson Amp ,Jnj ,Corporate Strategy ,Planning ,Corporate ,Industrial News ,Healthcare ,Life Sciences ,Generic ,Biosimilar Drugs ,